Information for "Dabigatran is non-inferior to warfarin in patients with atrial fibrillation: Results of the RE-LY trial"
Jump to navigation
Jump to search
Basic information
| Display title | Dabigatran is non-inferior to warfarin in patients with atrial fibrillation: Results of the RE-LY trial |
| Default sort key | Dabigatran is non-inferior to warfarin in patients with atrial fibrillation: Results of the RE-LY trial |
| Page length (in bytes) | 8,727 |
| Namespace ID | 0 |
| Page ID | 178671 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Number of subpages of this page | 0 (0 redirects; 0 non-redirects) |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | Kogando (talk | contribs) |
| Date of page creation | 19:43, 4 September 2009 |
| Latest editor | C Michael Gibson (talk | contribs) |
| Date of latest edit | 15:02, 8 September 2009 |
| Total number of edits | 12 |
| Total number of distinct authors | 2 |
| Recent number of edits (within past 30 days) | 0 |
| Recent number of distinct authors | 0 |
Page properties
| Magic word (1) |
|
| Transcluded templates (14) | Templates used on this page:
|